Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRISPR Companies Form Pact To Defend, Cross-License Gene Editing Patents

Executive Summary

Three CRISPR/Cas9 patent owners and four companies that license the intellectual property – CRISPR, Intellia, Caribou and ERS – signed a formal agreement to protect their patent rights and cross-license necessary IP while a patent interference proceeding is ongoing.

Advertisement

Related Content

Exonics Using CRISPR To Develop One-Time Treatment for Duchenne
Biogen Pays $1.25bn For Peace Of Mind Over Tecfidera, But Legal Wrangling Continues
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
J.P. Morgan Notebook Day 3: Regeneron, AstraZeneca CRISPR And Juno

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel